Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 13.963
Filtrer
1.
World J Gastroenterol ; 30(26): 3247-3252, 2024 Jul 14.
Article de Anglais | MEDLINE | ID: mdl-39086634

RÉSUMÉ

BACKGROUND: Multiple endocrine neoplasias (MENs) are a group of hereditary diseases involving multiple endocrine glands, and their prevalence is low. MEN type 1 (MEN1) has diverse clinical manifestations, mainly involving the parathyroid glands, gastrointestinal tract, pancreas and pituitary gland, making it easy to miss the clinical diagnosis. CASE SUMMARY: We present the case of a patient in whom MEN1 was detected early. A middle-aged male with recurrent abdominal pain and diarrhea was admitted to the hospital. Blood tests at admission revealed hypercalcemia and hypophosphatemia, and emission computed tomography of the parathyroid glands revealed a hyperfunctioning parathyroid lesion. Gastroscopy findings suggested a duodenal bulge and ulceration. Ultrasound endoscopy revealed a hypoechoic lesion in the duodenal bulb. Further blood tests revealed elevated levels of serum gastrin. Surgery was performed, and pathological analysis of the surgical specimens revealed a parathyroid adenoma after parathyroidectomy and a neuroendocrine tumor after duodenal bulbectomy. The time from onset to the definitive diagnosis of MEN1 was only approximately 1 year. CONCLUSION: For patients who present with gastrointestinal symptoms accompanied by hypercalcemia and hypophosphatemia, clinicians need to be alert to the possibility of MEN1.


Sujet(s)
Hypercalcémie , Néoplasie endocrinienne multiple de type 1 , Tumeurs de la parathyroïde , Parathyroïdectomie , Humains , Néoplasie endocrinienne multiple de type 1/chirurgie , Néoplasie endocrinienne multiple de type 1/diagnostic , Néoplasie endocrinienne multiple de type 1/complications , Néoplasie endocrinienne multiple de type 1/anatomopathologie , Mâle , Tumeurs de la parathyroïde/chirurgie , Tumeurs de la parathyroïde/diagnostic , Tumeurs de la parathyroïde/anatomopathologie , Tumeurs de la parathyroïde/complications , Adulte d'âge moyen , Hypercalcémie/diagnostic , Hypercalcémie/étiologie , Hypercalcémie/sang , Adénomes/chirurgie , Adénomes/diagnostic , Adénomes/anatomopathologie , Adénomes/sang , Tumeurs du duodénum/chirurgie , Tumeurs du duodénum/diagnostic , Tumeurs du duodénum/anatomopathologie , Hypophosphatémie/étiologie , Hypophosphatémie/diagnostic , Douleur abdominale/étiologie , Douleur abdominale/diagnostic , Tumeurs neuroendocrines/chirurgie , Tumeurs neuroendocrines/diagnostic , Tumeurs neuroendocrines/sang , Tumeurs neuroendocrines/anatomopathologie , Diarrhée/étiologie , Diarrhée/diagnostic , Dépistage précoce du cancer/méthodes , Gastroscopie , Résultat thérapeutique
2.
Medicine (Baltimore) ; 103(32): e39226, 2024 Aug 09.
Article de Anglais | MEDLINE | ID: mdl-39121266

RÉSUMÉ

RATIONALE: Small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare and aggressive gynecological tumor. We retrospectively analyzed the clinical manifestations and imaging findings of this patient and analyzed the relevant literature, with the aim of improving the ability of radiologists to differentiate SCCOHT from other ovarian tumors. PATIENT CONCERNS: We report a case of 36-year-old woman who was diagnosed with SCCOHT. MRI suggested a malignant tumor of the left ovary. The immunohistochemical markers shows SMARCA4 negativity. Notably, hypercalcemia was not detected. Microscopically, it was consistent with the large-cell variants. LESSIONS: Despite its rarity, SCCOHT should still be considered in the differential diagnosis of ovarian malignancies. When a young female patient presents with a large unilateral tumor on MRI with a predominant solid component and significant enhancement on the contrast enhanced scans, along with hypercalcemia, SCCOHT should be considered.


Sujet(s)
Carcinome à petites cellules , Hypercalcémie , Imagerie par résonance magnétique , Tumeurs de l'ovaire , Humains , Femelle , Tumeurs de l'ovaire/imagerie diagnostique , Tumeurs de l'ovaire/anatomopathologie , Tumeurs de l'ovaire/diagnostic , Adulte , Hypercalcémie/étiologie , Hypercalcémie/imagerie diagnostique , Carcinome à petites cellules/imagerie diagnostique , Carcinome à petites cellules/diagnostic , Imagerie par résonance magnétique/méthodes , Diagnostic différentiel
3.
BMC Pregnancy Childbirth ; 24(1): 483, 2024 Jul 17.
Article de Anglais | MEDLINE | ID: mdl-39020280

RÉSUMÉ

BACKGROUND: Hypercalcemia can be a rare contributor to acute pancreatitis (AP) in pregnancy. This is primarily due to primary hyperparathyroidism (PHPT), resulting from parathyroid carcinoma. We exhibited a case report to analyze the diagnosis and treatment during the onset of hypercalcemia-induced AP. CASE PRESENTATION: A 32-year-old primigravida presented with acute pancreatitis near full-term gestation. Following a cesarean delivery, there was a reduction in serum amylase and peripancreatic exudate, but her serum calcium concentrations persistently elevated over 4.0 mmol/L. Interventions to lower the hypercalcemia were only temporarily effective, until a high serum parathyroid hormone (PTH) concentration of 1404 pg/mL was detected. Ultrasound revealed a 31 mm × 24 mm hypoechoic oval nodule in the left lower lobe of the thyroid gland. She underwent a parathyroidectomy, resulting in a dramatic decrease in serum PTH level, from preoperative levels of 2051 pg/mL to 299 pg/mL just 20 minutes after removal. Similarly, her serum calcium declined from 3.82 mmol/L to 1.73 mmol/L within 24 hours postoperatively. The final histopathology suggested parathyroid carcinoma. CONCLUSION: When refractory hypercalcemia is present, serum PTH levels should be measured to determine PHPT. Parathyroidectomy is the optimal strategy for alleviating hypercalcemia and clarifying the underlying pathology.


Sujet(s)
Hypercalcémie , Pancréatite , Tumeurs de la parathyroïde , Parathyroïdectomie , Complications tumorales de la grossesse , Troisième trimestre de grossesse , Humains , Femelle , Hypercalcémie/étiologie , Hypercalcémie/sang , Tumeurs de la parathyroïde/complications , Tumeurs de la parathyroïde/chirurgie , Grossesse , Adulte , Pancréatite/étiologie , Pancréatite/complications , Pancréatite/sang , Complications tumorales de la grossesse/chirurgie , Hormone parathyroïdienne/sang , Hyperparathyroïdie primitive/chirurgie , Hyperparathyroïdie primitive/complications , Hyperparathyroïdie primitive/sang , Césarienne , Calcium/sang
5.
BMC Nephrol ; 25(1): 229, 2024 Jul 19.
Article de Anglais | MEDLINE | ID: mdl-39030472

RÉSUMÉ

BACKGROUND: Hypercalcaemia is a common manifestation of sarcoidosis but is sparingly described in gastrointestinal stromal tumours (GISTs). We describe a case of acute kidney injury and hypercalcemia resulting from simultaneous diagnosis of GIST and sarcoidosis, the presentation of which has not yet been reported. CASE PRESENTATION: A 61-year-old male presented with acute kidney injury and hypercalcemia, with elevated 1,25-dihydroxyvitamin D levels. Investigations demonstrated a large gastric antral mass which was resected and proven to be GIST. Histopathology of incidentally found liver nodules revealed non-necrotising epithelioid granulomas consistent with concomitant sarcoidosis. The hypercalcemia was successfully treated with bisphosphonate therapy, resection of the GIST and a four month course of corticosteroids, which was truncated due to a mycobacterial infection. CONCLUSIONS: Our case report is the first to describe hypercalcemia due to GIST and biopsy-proven sarcoidosis, thereby raising the possibility of a common pathophysiological pathway relating the two entities. We review the literature describing the mechanisms of hypercalcaemia in GIST and the association between GIST and sarcoidosis.


Sujet(s)
Tumeurs stromales gastro-intestinales , Hypercalcémie , Sarcoïdose , Humains , Hypercalcémie/étiologie , Mâle , Sarcoïdose/complications , Adulte d'âge moyen , Tumeurs stromales gastro-intestinales/complications
8.
Br J Hosp Med (Lond) ; 85(7): 1-5, 2024 Jul 30.
Article de Anglais | MEDLINE | ID: mdl-39078914

RÉSUMÉ

We present a rare case of a 40-year-old nulliparous lady, with no past medical or surgical history, who was diagnosed with metastatic squamous cell carcinoma of the right ovary that originated from a mature cystic ovarian teratoma. Our patient underwent debulking total abdominal hysterectomy, bilateral salpingo-oophorectomy and partial omentectomy followed by postoperative carboplatin and paclitaxel chemotherapy. Rapid disease progression ensued, complicated by severe parathyroid hormone-related protein-induced hypercalcaemia resistant to medical therapy. The patient was treated in a palliative manner and died five months after her diagnosis.


Sujet(s)
Carcinome épidermoïde , Hypercalcémie , Tumeurs de l'ovaire , Tératome , Humains , Femelle , Tumeurs de l'ovaire/anatomopathologie , Tumeurs de l'ovaire/complications , Tumeurs de l'ovaire/chirurgie , Tératome/complications , Tératome/chirurgie , Hypercalcémie/étiologie , Adulte , Carcinome épidermoïde/complications , Carcinome épidermoïde/anatomopathologie , Carcinome épidermoïde/chirurgie , Issue fatale , Hystérectomie/méthodes , Paclitaxel/usage thérapeutique
9.
Endocrinol Metab Clin North Am ; 53(3): 437-452, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39084818

RÉSUMÉ

Hypercalcemia during pregnancy is a risk for adverse maternal and fetal consequences. Although primary hyperparathyroidism is by far the most common etiology of hypercalcemia in pregnancy, an array of other etiologies of hypercalcemia associated with pregnancy and lactation have been described. Parathyroidectomy continues to be the preferred treatment for primary hyperparathyroidism. Medical management options are limited.


Sujet(s)
Hypercalcémie , Lactation , Complications de la grossesse , Humains , Hypercalcémie/étiologie , Hypercalcémie/thérapie , Grossesse , Femelle , Lactation/physiologie , Complications de la grossesse/thérapie , Complications de la grossesse/étiologie , Hyperparathyroïdie primitive/complications , Hyperparathyroïdie primitive/thérapie , Hyperparathyroïdie primitive/diagnostic
12.
Am J Case Rep ; 25: e943838, 2024 Jul 25.
Article de Anglais | MEDLINE | ID: mdl-39049471

RÉSUMÉ

BACKGROUND Benign parathyroid adenoma is a cause of hypercalcemia, which can lead to acute pancreatitis. Patients with acute pancreatitis are at risk for venous thrombosis. This report describes a 34-year-old woman with hypercalcemia due to parathyroid adenoma and acute pancreatitis associated with splenic vein and superior mesenteric vein thrombosis. CASE REPORT A previously healthy 34-year-old woman presented with severe epigastric pain that radiated to the back, associated with vomiting. Her abdominal examination was soft and lax, with epigastric and left upper quadrant tenderness. Pancreatitis with splenic and superior mesenteric veins thrombosis was diagnosed. The diagnosis was confirmed by an elevated serum lipase level and contrast-enhanced computed tomography (CT) of abdomen. Her serum calcium level was elevated. However, further workup revealed elevated parathyroid hormone (PTH) levels and radiological imaging showed parathyroid adenoma. She was diagnosed with hypercalcemia-induced pancreatitis secondary to hyperparathyroidism with intraabdominal venous thrombosis. The patient was initially treated conservatively, and later underwent parathyroidectomy after her condition was stabilized. The patient is currently in good condition, after a 2-year follow-up period. CONCLUSIONS Acute pancreatitis and thrombosis secondary to primary hyperparathyroidism (PHPT) are rare, but can lead to potentially fatal complications, especially in patients without symptoms of PHPT. This report highlights the importance of recognizing that hypercalcemia associated with parathyroid adenoma can result in acute pancreatitis, leading to hypercoagulable states and inflammation of adjacent vessels, including the splenic and mesenteric veins. To the best of our knowledge, this is second case report of acute pancreatitis with intraabdominal venous thrombosis secondary to PHPT.


Sujet(s)
Adénomes , Hypercalcémie , Pancréatite , Tumeurs de la parathyroïde , Thrombose veineuse , Humains , Femelle , Adulte , Tumeurs de la parathyroïde/complications , Tumeurs de la parathyroïde/diagnostic , Pancréatite/étiologie , Pancréatite/complications , Pancréatite/diagnostic , Thrombose veineuse/étiologie , Thrombose veineuse/diagnostic , Adénomes/complications , Adénomes/diagnostic , Hypercalcémie/étiologie , Hypercalcémie/diagnostic , Veine liénale/imagerie diagnostique , Veines mésentériques/imagerie diagnostique , Hyperparathyroïdie primitive/complications , Hyperparathyroïdie primitive/diagnostic , Hyperparathyroïdie primitive/étiologie , Parathyroïdectomie
13.
Eur J Cancer ; 208: 114122, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39047533

RÉSUMÉ

Metastatic pheochromocytomas and paragangliomas (PPGLs) are frequently associated with skeletal complications. Primary objective: to describe the frequency of adverse skeletal related events (SREs) in PPGL patients with bone metastases (BMs). Secondary objectives: to 1) identify predictive and prognostic factors for SREs and 2) obtain information on the effectiveness of bone resorption inhibitors in reducing SRE risk and improving outcomes in term of survival and SREs time onset. In this retrospective multicenter, multinational study, 294 PPGL patients were enrolled. SREs occurred in 90 patients (31 %). Fifty-five patients (19 %) had bone fractures, 47 (16 %) had spinal cord compression, and 11 (4 %) had hypercalcemia. Twenty-two patients (7 %) had more than one SRE. Sixty-four patients (22 %) underwent surgery, and 136 (46 %) underwent radiotherapy. SREs occurred a median of 4.4 months after diagnosis of BM (range, 0-246.6 months). Independent factors associated with reduced risk of SREs in multivariable analysis were I-131-MIBG radionuclide therapy (hazard ratio [HR], 0.536 [95 % CI, 0.309-0.932]; P = .027) and absence of liver metastases (HR, 0.638 [95 % CI, 0.410-0.992]; P = .046). The median overall survival duration was 5.3 year. In multivariable analysis, age younger than 48 years at PPGL diagnosis (HR, 0.558 [95 % CI, 0.3877-0.806]; P = .002), absence of liver metastases (HR, 0.618 [95 % CI, 0.396-0.965]; P = .034), treatment with bisphosphonates or denosumab (HR, 0.598 [95 % CI, 0.405-0.884]; P = .010), and MIBG radionuclide therapy (HR, 0.444 [95 % CI, 0.274-0.718]; P = .001) were associated with a reduced risk of death. SREs occur frequently and early in bone-metastatic PPGL patients but do not negatively impact survival. MIBG radionuclide therapy and treatment with bone resorption inhibitors are associated with favorable outcome.


Sujet(s)
Tumeurs de la surrénale , Tumeurs osseuses , Paragangliome , Phéochromocytome , Humains , Mâle , Femelle , Adulte d'âge moyen , Tumeurs osseuses/secondaire , Tumeurs osseuses/complications , Phéochromocytome/complications , Phéochromocytome/anatomopathologie , Phéochromocytome/mortalité , Études rétrospectives , Tumeurs de la surrénale/secondaire , Tumeurs de la surrénale/complications , Tumeurs de la surrénale/mortalité , Tumeurs de la surrénale/thérapie , Adulte , Sujet âgé , Paragangliome/complications , Paragangliome/anatomopathologie , Paragangliome/mortalité , Jeune adulte , Syndrome de compression médullaire/étiologie , Fractures osseuses/étiologie , Adolescent , Sujet âgé de 80 ans ou plus , Hypercalcémie/étiologie , Facteurs de risque , Agents de maintien de la densité osseuse/usage thérapeutique , Pronostic
14.
Nutrients ; 16(14)2024 Jul 12.
Article de Anglais | MEDLINE | ID: mdl-39064694

RÉSUMÉ

Background: Potential calcium-related adverse events of vitamin D supplement use have not been addressed in large-scale, real-world data so far. Methods: Leveraging data from the UK Biobank, encompassing 445,493 individuals aged 40-69, we examined associations of high 25-hydroxyvitamin (25(OH)D) levels ≥ 100 nmol/L and vitamin D supplementation with hypercalcemia (serum calcium > 2.6 mmol/L), kidney stones, and atherosclerosis assessments (pulse wave arterial stiffness index and carotid intima-medial thickness). Regression models were comprehensively adjusted for 49 covariates. Results: Approximately 1.5% of the participants had high 25(OH)D levels, 4.3% regularly used vitamin D supplements, and 20.4% reported regular multivitamin use. At baseline, the hypercalcemia prevalence was 1.6%, and 1.1% was diagnosed with kidney stones during follow-up. High 25(OH)D levels were neither associated with calcium-related adverse events nor atherosclerosis assessments. Vitamin D and multivitamin supplementation were associated with an increased prevalence of hypercalcemia (odds ratios and 95% confidence intervals: 1.46 [1.32-1.62] and 1.11 [1.04-1.18], respectively) but were neither associated with atherosclerosis nor future kidney stones. Conclusions: High 25(OH)D levels observable in routine care were not associated with any adverse outcome. Vitamin D users have a slightly higher prevalence of hypercalcemia, possibly due to co-supplementation with calcium, but without a higher atherosclerosis prevalence or risk of kidney stones.


Sujet(s)
Athérosclérose , Compléments alimentaires , Hypercalcémie , Calculs rénaux , Vitamine D , Humains , Hypercalcémie/épidémiologie , Hypercalcémie/induit chimiquement , Vitamine D/analogues et dérivés , Vitamine D/sang , Vitamine D/administration et posologie , Adulte d'âge moyen , Mâle , Femelle , Compléments alimentaires/effets indésirables , Royaume-Uni/épidémiologie , Calculs rénaux/épidémiologie , Calculs rénaux/sang , Sujet âgé , Athérosclérose/épidémiologie , Athérosclérose/étiologie , Adulte , Prévalence , Biobanques , Facteurs de risque , Calcium/sang , Calcium/administration et posologie ,
15.
Can Vet J ; 65(7): 638-642, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38952756

RÉSUMÉ

An 11-year-old neutered male large crossbreed dog was presented for investigation because of a 10-day history of progressive lethargy, hyporexia, and pyrexia. Physical and dermatological examinations were unremarkable. Blood biochemical analysis identified a marked total and ionized hypercalcemia and increased C-reactive protein concentration. Bicavitary computed tomography screening for causes of the dog's clinical and biochemical abnormalities identified a diffuse panniculitis. Histopathological examination of full-thickness skin biopsies was consistent with pyogranulomatous inflammation. Extensive histochemical staining revealed no infectious etiology. Complete clinical and biochemical remissions were observed after starting immunosuppressive, followed by tapering, doses of prednisolone, supporting an immune-mediated etiology. Key clinical message: Sterile, immune-mediated pyogranulomatous inflammation should remain a differential diagnosis for hypercalcemia in dogs. Significant dermatological disease may occur without visible abnormalities.


Panniculite pyogranulomateuse à médiation immunitaire avec hypercalcémie chez un chienUn grand chien croisé mâle castré de 11 ans a été présenté pour examen en raison d'antécédents de léthargie progressive, d'hyporexie et de pyrexie depuis 10 jours. Les examens physiques et dermatologiques étaient sans particularité. L'analyse biochimique du sang présentait une hypercalcémie totale et ionisée marquée et une concentration accrue de protéine C-réactive. Le dépistage par tomodensitométrie bicavitaire des causes des anomalies cliniques et biochimiques du chien a identifié une panniculite diffuse. L'examen histopathologique des biopsies cutanées de pleine épaisseur était compatible avec une inflammation pyogranulomateuse. Un examen par coloration histochimique extensive n'a révélé aucune étiologie infectieuse. Les rémissions cliniques et biochimiques complètes ont été observées après le début du traitement immunosuppresseur, suivies d'une diminution progressive des doses de prednisolone, confirmant une étiologie à médiation immunitaire.Message clinique clé:L'inflammation pyogranulomateuse stérile à médiation immunitaire doit rester un diagnostic différentiel de l'hypercalcémie chez le chien. Une maladie dermatologique importante peut survenir sans anomalies visibles.(Traduit par Dr Serge Messier).


Sujet(s)
Maladies des chiens , Hypercalcémie , Panniculite , Animaux , Chiens , Maladies des chiens/diagnostic , Maladies des chiens/traitement médicamenteux , Maladies des chiens/anatomopathologie , Mâle , Panniculite/médecine vétérinaire , Panniculite/diagnostic , Hypercalcémie/médecine vétérinaire , Prednisolone/usage thérapeutique , Immunosuppresseurs/usage thérapeutique
16.
Prim Care ; 51(3): 391-403, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39067966

RÉSUMÉ

This article provides a comprehensive overview of calcium physiology, clinical presentation with physical examination findings, laboratory assessment, differential diagnosis, and management of hypocalcemia and hypercalcemia for the primary care provider.


Sujet(s)
Calcium , Hypercalcémie , Hypocalcémie , Soins de santé primaires , Humains , Hypercalcémie/diagnostic , Hypercalcémie/thérapie , Hypocalcémie/diagnostic , Hypocalcémie/thérapie , Calcium/métabolisme , Diagnostic différentiel , Troubles du métabolisme du calcium/diagnostic , Troubles du métabolisme du calcium/thérapie
18.
Int J Artif Organs ; 47(6): 369-372, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38869042

RÉSUMÉ

In this study, we investigated the effectiveness of regional citrate anticoagulation continuous renal replacement therapy (RCA-CRRT) in reducing blood calcium levels in three patients with hypercalcemia crisis caused by different etiologies. The sodium citrate chelation of calcium ions was utilized as an anticoagulant for treating severely affected patients. By adjusting the citrate anticoagulant dose and monitoring treatment indicators, RCA-CRRT parameters were actively modified to alleviate the hypercalcemia crisis and provide time for surgery or specialized treatment. Two patients experienced rapid and effective reductions in blood calcium levels, allowing for further treatment, while the third patient exhibited a repeated increase in blood calcium, which eventually decreased after parathyroid adenoma resection, leading to clinical discharge. Our findings suggest that RCA-CRRT can help alleviate hypercalcemia crisis, stabilize the patient's internal environment, and provide valuable time for clinical treatment in cases of various medical conditions causing abnormal blood calcium elevations.


Sujet(s)
Anticoagulants , Thérapie de remplacement rénal continue , Hypercalcémie , Humains , Hypercalcémie/sang , Hypercalcémie/étiologie , Anticoagulants/usage thérapeutique , Anticoagulants/administration et posologie , Thérapie de remplacement rénal continue/méthodes , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Calcium/sang , Résultat thérapeutique , Acide citrique , Citrate de sodium
19.
J Surg Oncol ; 130(2): 310-321, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38881406

RÉSUMÉ

OBJECTIVES: Metastatic bone disease is estimated to develop in up to 17% of patients with melanoma, compromising skeleton integrity resulting in skeletal-related events (SREs), which impair quality of life and reduce survival. The objective of the study was to investigate (1) the proportion of melanoma patients developing SREs following diagnosis of bone metastasis and (2) the predictors for SREs in this patient cohort. METHODS: Four hundred and eighty-one patients with bone metastatic melanoma from two tertiary centers in the United States from 2008 to 2018 were included. The primary outcome was 90-day and 1-year occurrence of a SRE, including pathological fractures of bones, cord compression, hypercalcemia, radiotherapy, and surgery. Fine-Gray regression analysis was performed for overall SREs and pathological fracture, with death as a competing risk. RESULTS: By 1-year, 52% (258/481) of patients experienced SREs, and 28% (137/481) had a pathological fracture. At 90-day, lytic lesions, bone pain, elevated calcium and absolute lymphocyte, and decreased albumin and hemoglobin were associated with higher SRE risk. The same factors, except for decreased hemoglobin, were shown to predict development of SREs at 1-year. CONCLUSION: The high incidence of SREs and pathological fractures warrants vigilance using the identified factors in this study and preventative measures during clinical oncological care.


Sujet(s)
Tumeurs osseuses , Fractures spontanées , Mélanome , Humains , Mélanome/anatomopathologie , Mélanome/secondaire , Mâle , Tumeurs osseuses/secondaire , Femelle , Études rétrospectives , Adulte d'âge moyen , Sujet âgé , Fractures spontanées/étiologie , Études de suivi , Pronostic , Facteurs de risque , Adulte , Hypercalcémie/étiologie , Taux de survie , Tumeurs cutanées/anatomopathologie
20.
Acta Clin Belg ; 79(3): 229-233, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38934586

RÉSUMÉ

OBJECTIVES: Sarcoidosis is a multi-system granulomatous disease of unknown origin. It is mainly thought of as a lung disease but it can affect any organ system. Sinus and endocrine dysfunctions are described but are rare and seldomly linked with sarcoidosis. METHODS: Here we describe a case of a young Caucasian man who already visited multiple care givers for sinusitis, erectile dysfunction and anorexia. He presented at the emergency department with fever and emaciation, polyuria and polydipsia. The results of the blood sampling revealed a hypercalcaemia as well as abnormal thyroid function. RESULTS: After biochemical, radiological and histopathological workup, he was diagnosed with pulmonary sarcoidosis. Treatment with corticosteroids resulted in resolution of the sinusitis and normalisation of the calcemia, as well as the thyroid function while the impotence, polydipsia and polyuria remained. Elaboration revealed extra-pulmonary involvement of the sarcoidosis with dysfunction of the hypothalamic-pituitary axis with hypogonadotropic hypogonadism and diabetes insipidus due to a sellar mass. CONCLUSION: This is a rare case of systemic sarcoidosis with both thoracic and extra thoracic manifestations, with pituitary and sinus involvement. It shows that sarcoidosis can affect any organ system and diagnosis can be difficult in case of extrapulmonary manifestations.


Sujet(s)
Hypercalcémie , Sinusite , Humains , Mâle , Hypercalcémie/diagnostic , Hypercalcémie/étiologie , Adulte , Sinusite/complications , Sinusite/diagnostic , Sarcoïdose/complications , Sarcoïdose/diagnostic , Sarcoïdose/traitement médicamenteux , Sarcoïdose/physiopathologie , Sarcoïdose pulmonaire/complications , Sarcoïdose pulmonaire/diagnostic , Sarcoïdose pulmonaire/physiopathologie , Sarcoïdose pulmonaire/traitement médicamenteux , Maladies hypothalamiques/diagnostic , Maladies hypothalamiques/complications
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE